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Antibodies Elicited by Inactivated Propionibacterium
acnes-Based Vaccines Exert Protective Immunity and
Attenuate the IL-8 Production in Human Sebocytes:
Relevance to Therapy for Acne Vulgaris
Teruaki Nakatsuji1,2, Yu-Tsueng Liu3, Cheng-Po Huang2,3, Richard L. Gallo1,2 and Chun-Ming Huang1,2,3
Propionibacterium acnes is a key pathogen involved in the progression of inflammation in acne vulgaris. We
examined whether vaccination against P. acnes suppressed P. acnes-induced skin inflammation. Inactivation of
P. acnes with heat was employed to create a P. acnes-based vaccine. Intranasal immunization in mice with this
inactivated vaccine provoked specific antibodies against P. acnes. Most notably, immunization with inactivated
vaccines generated in vivo protective immunity against P. acnes challenge and facilitated the resolution of ear
inflammation in mice. In addition, antibodies elicited by inactivated vaccines effectively neutralized the
cytotoxicity of P. acnes and attenuated the production of proinflammatory cytokine IL-8 in human sebocyte SZ95
cells. Intranasal immunization using heat-inactivated P. acnes-based vaccines provided a simple modality to
develop acne vaccines. These observations highlight the concept that development of vaccines targeting
microbial products may represent an alternative strategy to conventional antibiotic therapy.
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INTRODUCTION
Propionibacterium acnes, a gram-positive anaerobic bacter-
ium, is a member of the resident bacterial flora and mostly
resides in pilosebaceous follicles. It has been known that the
bacterium plays a critical role in the development of
inflammatory acne vulgaris, which is the most common
disease of human skin afflicting up to 80% of individuals
through their lives (Cunliffe and Gollnick, 2001b; Leyden,
2001; Bojar and Holland, 2004). In inflammatory acne
lesions, the follicular epithelium is damaged and a dermal
inflammation occurs. So far, several mechanisms of devel-
oping acne associated with P. acnes have been proposed. The
mechanism for the onset of acne can generally be divided
into two stages. The first stage is comedo formation, which is
characterized by the initiation of inflammatory events before
hyperproliferation of the follicular epithelia (microcomedo)
(Jeremy et al., 2003); the second stage is the occurrence of
inflammation and disruption of follicular epithelia. Although
the involvement of P. acnes in the initiation of comedo-
genesis is still controversial (Cunliffe and Gollnick, 2001a),
they can aggravate or intensify abnormal desquamation
once overgrowth and colonization of P. acnes in the micro-
comedo occur (Leeming et al., 1988; William J Cunliffe,
2001). P. acnes produces a number of extracellular enzymes
and metabolites that can directly damage host tissues
(Hoeffler, 1977; Holland et al., 1981; Cove et al., 1983;
Hoffler et al., 1985). In addition, it was also widely accepted
that inflammation in acne lesions may be induced by host
immune reactions to P. acnes. Chemotactive substances
released from the bacteria attract polymorphonuclear leuko-
cytes (Webster and Leyden, 1980). It has also been reported
that P. acnes stimulates production of proinflammatory
cytokines, including IL-1b, IL-8, IL-12, and tumor necrosis
factor-a. The P. acnes-induced cytokine productions have
known to be mediated by toll-like receptor (TLR) 2 (Kim et al.,
2002; Kim, 2005; Nagy et al., 2006).
Reduction in P. acnes numbers by antimicrobial agents
correlates with clinical improvement of acne in patients,
therefore antibiotic therapy has been a mainstay of treatment
for acne over the past 25 years. However, P. acnes strains
with clinically significant antibiotic resistance, and multiple
drug resistance were identified from acne patients with long-
term antibiotic treatment (Eady et al., 2003; Nord and Oprica,
2006). More recently, it has been demonstrated that biofilm
formation by P. acnes increases resistance against antimicro-
bial agents (Coenye et al., 2007). In addition, P. acnes resists
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killing by phagocytes and is able to survive in macrophages
(Webster et al., 1985b). These problems may be the roots of
clinical failure to treat acne. In the cases of mild and severe
acne, acne lesions are observed not only on the face, but also
on the chest, shoulders, or back of the patient. In such cases,
topical treatment with anti-acne agents in large areas or for
long periods of time may produce side effects, and systemic
antibiotic therapy may nonspecifically kill skin bacteria,
which impacts the homeostasis of skin-resident microflora
(Ochsendorf, 2006). Isotretinoin, 13-cis-retinoic acid, is a
vitamin A-derived retinoid that has been widely prescribed
for systemic treatment of severe acne. This agent acts
primarily by decreasing the size of the sebaceous glands
and reducing sebum production by up to 90%, thereby
inhibiting the growth of P. acnes and subsequent inflamma-
tion (Clarke et al., 2007). However, its use has now been
highly regulated because of its adverse effects, and it is not
appropriate for most acne patients. Currently available
treatments for acne lesions are often only palliative and
minimally effective while treatment is maintained. In most
cases, when treatments are discontinued, recurrence of acne
often results. Therefore, acne is still one of the skin diseases
that require alternative approach of treatments, although
various antibiotics, medicines, and therapies for acne have
been developed.
It has been demonstrated that IgG-coated bacteria were
found in comedones of acne patients, suggesting that IgG in
comedones was derived from the serum and selectively
accumulated in the follicle (Knop et al., 1983). This
observation inspired us to hypothesize that suppression of
P. acnes by anti-P. acnes antibody may have a potential to
prevent its progression and pathogenicity. In this study, we
demonstrated protective effects of vaccination with heat-
killed P. acnes on P. acnes-induced inflammation. More
importantly, the model employing the production of proin-
flammatory cytokines from human sebocytes provides a
relevance to the vaccine therapy for acne vulgaris. Further-
more, inactivated P. acnes-based vaccines afford a straight-
forward modality for vaccine manufacturing.
RESULTS
P. acnes-induced inflammation in mice
To induce a model of P. acnes inflammation, we injected 107
colony-forming units (CFU) of living P. acnes intradermally
into mouse ears. Significant cutaneous erythema (Figure 1a,
left ear), ear swelling, and granulomatous response (Figure
1b) were observed in P. acnes-injected ear 24 hours after the
bacterial injection, but neither of them were induced by
phosphate-buffered saline (PBS) injection (Figure 1a, right
ear, and c). Histological observation revealed that injection of
P. acnes induced a considerable increase in the number of
infiltrated inflammatory cells (Figure 1b).
Immunogenicity of heat-killed P. acnes
To generate sufficient and specific antibody against P. acnes,
mice were intranasally immunized with heat-killed
P. acnes three times at a 3-week interval. Serum was
collected 1 week after the third inoculation. Data from
western blot indicated that two main components (approxi-
mately 64 and 250 kDa) of P. acnes were immunoreactive to
antibodies elicited by heat-killed inactivated P. acnes
(Figure 2, lane 1). No immunoreactivity to P. acnes lysates
was detected if serum from PBS-injected mice was used
(Figure 2, lane 3). In addition, antibodies in the sera from
a
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Figure 1. The inflammation in mouse ears after P. acnes injection. Ears of
ICR mice were injected subcutaneously with 107 CFU per 20ml of P. acnes
(left ear) or 20 ml of PBS (right ear). (a) Inflammation-induced ear redness was
visualized 24 hours after injection. (b, c) Increase in ear thickness and
infiltrated inflammatory cells (arrows) surrounding the injected site of P. acnes
(arrowhead) were observed in (b) a hematoxylin-and-eosin-stained frozen
section of P. acnes-injected ear. (c) Staining PBS-injected ear serves as a
control. Bars¼ 0.2mm.
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Figure 2. Antibody production after injection with heat-killed P. acnes.
Lysate of P. acnes (7 mg) was separated by SDS-PAGE (10% acrylamide) and
then subjected to western blotting using an antiserum obtained from
heat-killed P. acnes (lane 1), S. epidermidis-immunized mice (lane 2), or
PBS-injected mice (lane 3) as a primary antibody; immunoreactivity was
developed using goat anti-mouse IgG/horseradish peroxidase complex and
western lighting chemiluminescence kit (PerkinElmer, Boston, MA).
Molecular weights (kDa) are indicated.
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P. acnes-immunized mice did not cross-react with proteins in
Staphylococcus epidermidis (ATCC 12228) (Figure 2, lane 2),
indicating the specificity of anti-P. acnes antiserum. Intrana-
sal administration also demonstrated the competence of
inactivated P. acnes-based vaccines in inducing mucosal
immunity.
In vivo protective effect of inactivated P. acnes-based vaccines
To determine the protective immunity elicited by vaccination
with heat-killed P. acnes, the ear of the vaccinated mouse
was intradermally challenged with living P. acnes
(1107CFU). The increase in P. acnes-induced ear thickness
was recorded until thickness subsided (Figure 3). A biphasic
pattern of changes in ear thickness was observed. In the PBS-
inoculated mice, ear thickness increased rapidly more than
two-fold (215.8%) on the first day, decreased on the second
day, then rebounded (225.0%) on the seventh day, and
recovered 78 days after bacterial challenge. The increase in
ear thickness in both phases (P¼0.04 at 24 hours and
P¼0.0013 on 7 days post-challenge) was significantly
suppressed when mice were immunized with inactivated
P. acnes-based vaccines. In P. acnes-immunized mice, the
increase in ear thickness completely subsided 22 days after
bacterial challenge. These data strongly demonstrated that
vaccination with inactivated P. acnes-based vaccines sup-
pressed the bacterial progression and facilitated the recovery
of P. acnes-induced inflammation.
In vitro neutralization of P. acnes-induced proinflammatory
cytokine production in human sebocytes
A human SZ-95 sebocyte was utilized with the aim of
establishing a model for evaluating the potency of anti-
P. acnes antiserum to neutralize the cytotoxicity of P. acnes. It
has been shown that activation of TLR2 expressed in human
sebocytes with P. acnes notably increased cytokine IL-8
production (Nagy et al., 2006). In addition, elevation of IL-8
and its gene expression was observed in skin biopsies of
patients with inflammatory acne vulgaris (Trivedi et al., 2006;
Abd El All et al., 2007). Thus, the capability of anti-P. acnes
antiserum to neutralize P. acnes-induced IL-8 production in
human sebocytes was examined. Sebocytes produced
1.2 ngml1 of IL-8 when they were treated with the bacteria
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Figure 3. In vivo protective immunity in the mice immunized with
inactivated P. acnes-based vaccines. A total of 20 ml aliquot of living P. acnes
(1107CFU) suspended in PBS was intradermally injected into left ears of
mice immunized with heat-killed P. acnes or PBS (n¼8 or 7, respectively). As
a control, an equal volume of PBS was injected into the right ears of the same
mice. Ear thickness was measured with a micro-caliper at the indicated
times post-bacterial challenge. The ear thickness of P. acnes-injected ear
was calculated as % of a PBS-injected control. Bars represent
mean±SE (*Po0.05, **Po0.005, ***Po0.0005 by Student’s t-test).
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Figure 4. Neutralization of cytotoxicity of P. acnes and P. acnes-induced
IL-8 production in human sebocytes by anti-P. acnes antiserum. P. acnes was
pre-incubated with anti-P. acnes antiserum or anti-PBS control serum (2.5%
(v/v)), in which complements were deactivated by heating for 2 hours. (a) For
neutralization of IL-8 production, the immortalized human sebocytes, SZ-95
(3106 cells), were co-cultured with 300ml of the pre-incubation mixtures
containing 1.5 108CFU of P. acnes and 7.5 ml antiserum for 8 hours.
Measurement of IL-8 in the culture medium was carried out by ELISA assays.
P. acnes-induced IL-8 production was calculated as the difference of amount
between with and without P. acnes. (b) For neutralization of cytotoxicity of
P. acnes, the sebocytes (2 105 cells per well) were co-cultured with 100 ml
of the neutralization reaction mixtures containing 2106CFU of P. acnes
and 2.5 ml antiserum for 18 hours. As a control, an equal amount of PBS was
added instead of P. acnes. As a background, Triton-X was added to get a final
concentration of 0.1% (v/v) to kill sebocytes. After incubation, cell viability of
sebocytes was determined with P-nitrophenyl phosphate disodium, and
cytotoxicity of neutralizing mixture was calculated as follows: (no P. acnes
groupP. acnes added group)C(no P. acnes groupbackground group)
100 (%). Bars represent mean±SE (n¼ 5). Data were analyzed by Student’s
t-test (**Po0.005).
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that were pre-incubated with serum from PBS-inoculated
mice (Figure 4a). By contrast, pre-incubation with anti-P.
acnes antiserum effectively decreased P. acnes-induced IL-8
production to 0.59 ngml1 (P¼0.0015). Pre-incubation of
2 hours with antisera did not influence the growth of P. acnes
as determined by CFU (Figure S2). These results suggest that
anti-P. acnes antiserum attenuated P. acnes-induced IL-8
production in sebocytes without affecting bacterial survival.
The ability of anti-P. acnes antiserum to neutralize the
cytotoxicity of P. acnes was also determined. After incubation
with serum from PBS-inoculated mice, P. acnes triggered
29.3% of sebocyte death (Figure 4b). On the other hand, the
dead sebocytes were dramatically reduced to 12.7%
(P¼0.003) when cells were treated with neutralized P.
acnes. These data indicated that antibodies evoked by
inactivated P. acnes-based vaccines efficiently counteracted
the P. acnes-induced inflammation.
DISCUSSION
In acne lesions, a partially occluded follicle creates an ideal
anaerobic environment for P. acnes to multiply. Conse-
quently, the increase of P. acnes and its enzymes, virulence
factors, and pattern recognition ligands stimulated the skin
resulting in inflammation and acne lesions (Leyden, 2001;
William J Cunliffe, 2001; Bojar and Holland, 2004). Our
results indicated that injection of P. acnes into ICR mouse
ears induced an increase in the ear thickness (Figure 1) and
granulomatous response (Figure 1b). One day after injection,
we observed that P. acnes was surrounded by a densely
packed granulomatous infiltrate. Although ears injected with
S. epidermidis (ATCC 12228; 108 CFU), an aerobic skin
commensal, induced a minor swelling, this swelling rapidly
subsided within 4 days (data not shown). Although multiple
injections of P. acnes into mouse ears may cause tissue
necrosis, it is worth investigating whether TLR2 tolerance
induced by a repeat of intraperitoneal injection of P. acnes
could alter host sensitivity to bacterial infection (Medvedev
et al., 2006). Mice produce little or no triglycerides, a fact
that has hindered the development of an animal model for
studying the lipogenesis in acne lesions (Webster et al.,
1981b). The rabbit ear model has a lack of bacterial
colonization and inflammation (Mirshahpanah and Maibach,
2007). In addition, the use of rabbits may be inconvenient for
vast vaccinations. Rhino mice with utricles that create larger
follicle size have been widely used for screening anti-acne
drugs (Takaoki and Kawaji, 1980). However, as Rhino mice
with deficits in immune system cannot produce antibodies
against thymus-dependent antigens (Takaoki and Kawaji,
1980), we thus created inflammatory responses in an ICR
mouse strain as an animal model (De Young et al., 1984,
1985) to evaluate the potency of inactivated P. acnes-based
vaccines. In most cases of acne, P. acnes is thought to
colonize on the skin surface and/or within sebaceous
follicles. Bacteria could enter the dermis once the follicular
wall was ruptured (Kligman, 1974). Injection of P. acnes into
mouse ears may represent an animal model for the
granulomatous type of acne inflammation that follows
follicular rupture.
Many vaccine development approaches are under investi-
gation, but the one straightforward method is the use of
intranasally administered killed whole pathogen preparations.
It has known that P. acnes itself is a potent immunomodulator
(Mussalem et al., 2006). Our data illustrated that mice
immunized with heat-killed P. acnes produced antibodies
against two P. acnes-specific proteins with molecular weights
at approximately 64 and 250kDa. Antibodies against P. acnes
can be frequently found in severe acne patients (Webster et al.,
1985a). In some cases, there is a correlation between the
severity of acnes and titers of antibodies against P. acnes in
patients’ sera (Holland et al., 1986; Ingham et al., 1987;
Ashbee et al., 1997). The antibodies are generated against P.
acnes exocellular enzymes, or cell wall/membrane fractions,
such as polysaccharide, carbohydrate, or membrane-binding
proteins in acne patients (Dalen et al., 1980; Iversen et al.,
1985; Webster et al., 1985a; Ingham et al., 1987; Lodes et al.,
2006). However, acne lesions recurred often, despite anti-
bodies against P. acnes having been generated in those
patients. One possible explanation could be that those acne
patients may not produce sufficient protective antibodies
against key virulence factors of P. acnes for the suppression
of bacterial progression and the prevention of recurrence.
Additionally, it is worth examining whether acne patients
produced antibodies against the two antigens (approximately
64 and 250kDa) that were elicited in the mice vaccinated with
heat-killed P. acnes (Figure 2). As mucosal vaccination with
most inactivated organisms induced a relatively weak immune
response, adjuvant such as Vibrio cholerae cholera toxin or E.
coli heat-labile enterotoxin was frequently administrated along
with antigen to nasal cavity. However, these adjuvants may
cause adverse effects (Spangler, 1992). The high immunogeni-
city of heat-killed P. acnes without adjuvants suggested that
inactivated P. acnes exerted a self-adjuvant effect. Most
importantly, the use of inactivated P. acnes-based vaccines
eliminates the time-consuming steps required for antigen
purification. Furthermore, intranasal immunization circum-
vents the intrinsic problems associated with multiple needle
injections. Thus, P. acnes-based vaccines are beneficial for
large-scale and rapid vaccine production.
The vaccination effectively suppressed P. acnes-induced
ear swelling and expedited the recovery of ear inflammation
(Figure 3). Ear thickness was measured regularly for 78 days,
revealing a biphasic ear-swelling pattern. This is consistent
with previous findings illustrating a biphasic change in the
activity of the mouse reticuloendothelial system after
intraperitoneal injection with phenol-treated P. acnes (Ko-
bayashi et al., 1980). The biphasic pattern was interpreted by
the fluctuation in the number of macrophages and other host
cells in the inflamed skins. We also vaccinated ICR mice with
heat-killed P. acnes (1108CFU) one day after intradermally
challenging with living P. acnes (1107CFU) (Figure S1).
Although ear swelling was suppressed during vaccination, a
substantial increase in ear thickness still existed 22 days post-
bacterial challenge. The result was different with that of mice
vaccinated with heat-killed P. acnes for 10 weeks (Figure 3)
before bacterial challenge. Ear swelling in mice vaccinated for
10 weeks was rapidly subsided 22 days after bacterial
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challenge. One possible explanation for this distinction is that
vaccination after bacterial challenge may not evoke sufficient
antibodies to effectively combat bacteria. It has been docu-
mented that inflammation in acne lesions was initiated by the
production of proinflammatory cytokines after interaction of
P. acnes to TLR2 (Kim et al., 2002; Kim, 2005; Nagy et al.,
2006). In addition, it has been known that activation of TLR2
expressed in human sebocytes, one of target cells of P. acnes,
with P. acnes released tremendous cytokine IL-8 (Nagy et al.,
2006; Abd El All et al., 2007). The prevalence of P. acnes in the
sebocytes of sebaceous glands is highly associated with acne
progression. Sebocytes were involved in skin immunity by
producing antimicrobial substances and proinflammatory
cytokines (Nagy et al., 2006). Our data revealed that anti-
P. acnes antiserum effectively neutralized the cytotoxicity of
P. acnes and lowered P. acnes-induced IL-8 production in
human sebocytes. The peptideglycan–polysaccharide com-
plexes and lipoteichoic acids, two major cell wall components
in the gram-positive bacteria, can stimulate the release of
proinflammatory cytokines from monocytes (Mattsson et al.,
1993). Webster et al. (1985a) demonstrated that a carbohy-
drate-structured component of P. acnes was highly antigenic in
severe acne patients. Moreover, Basal et al. (2004) found a
major 96kDa antigenic component, which stimulated the
production of IL-8 and tumor necrosis factor-a from human
peripheral blood mononuclear cells. Taken together, inacti-
vated P. acnes-based vaccines may diminish inflammation via
blocking the TLR2 signaling in sebocytes. Ingham et al. (1987)
detected antibodies against P. acnes exocellular enzymes, that
is, lipase and hyaluronate lyase, in normal subjects and acne
patients. They, however, could not find any differences of the
antibody titers between these two groups, suggesting that
the amounts of antigens secreted from P. acnes existing in the
sebaceous follicles of acne patient may not be enough for
humans to elevate antibody titers. Thus, boosting sufficient
antibodies against P. acnes may be a future direction to
develop therapeutic acne vaccines.
It has been reported that mice administrated with P. acnes
enhanced the resistance to influenza virus (Gangemi et al.,
1983) and tumor formation (Murano and Cummins, 1989;
Mussalem et al., 2006) as well as augmented phagocytic
activities (Webster et al., 1979, 1981a; Gangemi et al., 1983).
These data implied that inactivated P. acnes vaccines may
increase host immunity. Adversely, vaccination targeting
whole bacterium may lack specificity (Kobayashi et al.,
1980). Genomic (Bruggemann et al., 2004; Bruggemann,
2005) and/or proteomics approached may help in antigen
selection for the development of component acne vaccines.
We recently selected a surface sialidase from the P. acnes
genome as an antigen for the development of a component
acne vaccine (Nakatsuji et al., 2008). The bacterial specifi-
cities of P. acnes- and sialidase-based vaccines will be
addressed in the future studies.
Data from bacterial counting on agar plates showed that
P. acnes did not change its growth after incubation with
anti-P. acnes antiserum (Figure S2). Additionally, counting
bacteria from homogenized ear skins indicated that intranasal
vaccination did not statically alter the colonization of
P. acnes (data not shown). To confirm this phenomenon, we
counted P. acnes in fluids extracted from an implanted tissue
chamber in vaccinated and nonvaccinated mice (Nakatsuji
et al., 2008). Consistently, vaccination did not change the
multiplication of P. acnes in mice (Figure S3). These results
suggested that intranasal immunization with inactivated
P. acnes-based vaccines may not produce sufficient bactericidal
antibodies. On the other hand, the immunization with an acne
vaccine that has no bactericidal action may perform no risk of
destroying the balance of skin microflora. Although the killed
strains of P. acnes and/or Staphlococci have been used as acne
vaccines and named as acnevac or autovaccines (Zaluga,
1998), their potency in inhibiting the production of proin-
flammatory cytokines in human skin cells is undetermined. In
conclusion, we demonstrated that vaccination with inactivated
P. acnes suppressed inflammation in vitro and in vivo. The fact
that antibodies effectively suppressed the production of
proinflammatory cytokine IL-8 in human sebocytes highlights
inactivated P. acnes-based vaccines as a novel treatment for
acne vulgaris.
MATERIALS ANS METHODS
Culture of P. acnes
Propionibacterium acnes ATCC 6919 (American Type
Culture Collection, Manassas, VA) was cultured on Brucella
broth agar (BD, Sparks, MD), supplemented with 5% (v/v)
defibrinated sheep blood (LAMPIRE Biological Laboratories,
Pipersville, PA), vitamin K (5 mgml1, Remel, Lenexa, KS),
and hemin (50 mgml1, Remel, Lenexa, KS), under an
anaerobic condition using Gas-Pak (BD, Sparks, MD) at
371C. Single colony was inoculated in Reinforced Clostri-
dium Medium (Oxford, Hampshire, England) and cultured at
371C until reaching OD600¼ 1.0–3.0 (logarithmic growth
phase) under the anaerobic condition. Bacteria were har-
vested by centrifugation at 5,000 g for 10minutes, washed
with PBS three times, and suspended to appropriate amount
of PBS for the experiments.
Intranasal vaccination of mice with heat-killed P. acnes
Female 8-week-old ICR mice (Harlan, Indianapolis, IN) were
used in all experiments. Mice were housed according to
institutional guidelines. P. acnes was suspended in PBS and
inactivated by heating bacteria at 601C for 30minutes. After
inactivation, P. acnes was unable to grow on an agar plate
(data not shown). Inactivated P. acnes was harvested by
centrifuging at 5,000 g for 5minutes and re-suspended to
appropriate amount of PBS. An amount of 25 ml aliquot of
inactivated-P. acnes suspension (1108CFU) was intrana-
sally inoculated to an ICR mouse every 3 weeks. The second
and third boosts were given at the same manner as the first
inoculation. Control mice were inoculated with an equal
volume of PBS or S. epidermidis (ATCC 12228).
Propionibacterium acnes-induced inflammation
An amount of 20 ml aliquots of living P. acnes (1 107CFU)
suspended in PBS was intradermally injected in the central
portion of the left ear. As a control, 20 ml of PBS was injected
into the right ear of the same mice. For histological
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observation, the ear was cross-sectioned, stained with
hematoxylin and eosin (Sigma diagnostics, St Louis, MO),
and viewed on a Zeiss Axioskop2 plus microscope (Carl
Zeiss, Thornwood, NY). To examine in vivo protective
effects, ears of immunized mice and their controls were
challenged with P. acnes. The increase in ear thickness was
measured using a micro caliper (Mitutoyo, Japan) after the
bacterial challenge. The increase in ear thickness of P. acnes-
challenged ear was calculated as % of a PBS-injected control.
Detection of antibody against P. acnes by western blotting
After centrifugation, P. acnes pellet was suspended in 8M
urea, homogenized by beating with 0.1mm glass beads for
2minutes, diluted with sample buffer (125mM Tris-HCl
buffer, pH 6.8, containing 4% (w/v) SDS, 10% (w/v) glycerol,
5% (v/v) 2-mercaptoethanol and 0.002% bromophenol blue),
and boiled for 2minutes. The sample (7 mg proteins) was
electrophoresed in 10% (w/v) polyacrylamide gel (Bio-Rad,
Hercules, CA) and electrophoretically transferred onto poly-
vinyliden difluoride membranes (Millipore, Billerica, MA) for
60minutes at a current of 100V. The membranes were pre-
incubated for 30minutes in PBS containing 5% (w/v) skim
milk, and then incubated with anti-P. acnes antiserum or
control sera (1:1,000 dilution) at 41C overnight. Bound
antibodies were detected with goat anti-rabbit peroxidase
conjugated IgG (1:5,000 dilution, Promega, Madison, WI),
and the peroxidase activity was developed with Western
lighting chemiluminescence kit (PerkinElmer, Boston, MA).
In vitro neutralization
The immortalized human sebocyte line, SZ95 (Zouboulis
et al., 1999), was cultured in Sebomed basal medium
(Biochrom, Berlin, Germany) supplemented with 5 ngml1
human recombinant epidermal growth factor (Sigma,
St Louis, MO), 10% (v/v) heat-inactivated fetal bovine serum
(Mediatech Inc., Herndon, VA), at 371C under an atmosphere
of 5% (v/v) CO2 in air. P. acnes was cultured as described
above, washed with PBS by centrifuging, and pre-incubated
with 2.5% (v/v) anti-P. acnes antiserum or control sera, in
which complements were deactivated by heating at 561C for
30minutes, at 371C for 2 hours. For neutralization of IL-8
production, the sebocytes (3106 cells) were co-cultured
with 300ml of the pre-incubation mixtures containing
1.5108CFU of P. acnes and 7.5 ml antiserum for 8 hours.
As a background, sebocytes were incubated with antiserum
alone. After centrifuging to remove bacteria, the concentra-
tions of IL-8 in the culture medium were determined by ELISA
using a Quantikine human IL-8 set (R & D Systems Inc.,
Minneapolis, MN). P. acnes-induced IL-8 production was
calculated as the difference of amounts between with and
without P. acnes. For neutralization of cytotoxicity of
P. acnes, sebocytes (2105 cells per well) were co-cultured
with 100ml of a pre-incubation mixture containing 2106
CFU of P. acnes and 2.5 ml of antiserum for 18 hours. As a
control, an equal amount of PBS was added instead of
P. acnes. As a background, Triton-X was added to get a final
concentration of 0.1% (v/v) to lyse sebocytes. After incuba-
tion, cell viability of sebocytes was determined with acid
phosphatase assay (Martin and Clynes, 1991). Cells were
washed with PBS three times and incubated with 100ml of
10mM P-nitrophenyl phosphate in acid phosphatase assay
buffer (1M sodium acetate buffer, pH 5.5, containing 0.1% (w/
v) Triton X-100) for 1 hour at 371C. Then, 10ml of 1 N NaOH
was added to stop the reaction, and absorbance at 405nm was
measured. Cytotoxicity of neutralizing mixture was calculated
as follows: (the OD405 difference between without and with
P. acnes treatment)C(the OD405 difference between without
P. acnes and with Triton-X treatment)100 (%).
Statistical analysis
Data are presented as mean±SE. The Student’s t-test was
used to assess the significance of independent experiments.
The criterion Po0.05 was used to determine statistical
significance.
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